Stockreport

Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham [Yahoo! Finance]

Artiva Biotherapeutics, Inc.  (ARTV) 
PDF NK cell platform and expects an H1 efficacy data readout in at least 15 RA patients (most with =6 months follow-up) alongside updates on potential pivotal-trial discussi [Read more]